Clinical trials: Collagen Disorders
Skin Condition
Efficacy Evaluation of Triple up® Collagen Drink on Skin Condition
To assess Triple up® Collagen Drink on skin condition improvement
- Trial name
- NCT04225091
- Testing
- Testing product, Blank
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA)
Controlling Hyperactive Immunity With Long-lived Lymphocytes
This study is a Phase 1/2, open-label clinical trial to test an experimental treatment called QEL-005 in adults with two autoimmune conditions: diffuse cutaneous systemic sclerosis (dcSSc) and difficult-to-treat rheumatoid…
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
- Trial name
- CHILL (NCT07473154)
- Testing
- QEL-005
- Where
- 10 sites in Germany, Spain and 1 more
- Volunteers
- 16 people
- Sponsor
- Quell Therapeutics Limited
Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Trial name
- ONSET (NCT06905288)
- Testing
- Secukinumab
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Cataract, Glaucoma
Oculusgen (Ologen) Collagen Matrix Implant for Phaco-Trabeculectomy in Primary Glaucoma: A Case-Control Study
The objective of this study is to determine the safety and effectiveness of the OculusGen™ (ologen) Biodegradable Collagen Matrix Implant in hacotrabeculectomy surgery.
- Trial name
- NCT00687791
- Testing
- ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
The objective of this study is to compare the efficacy and safety of RGN-137 topical gel with that of placebo gel for treatment of junctional epidermolysis bullosa (JEB) or dystrophic epidermolysis bullosa (DEB).
- Trial name
- CELEB (NCT03578029)
- Testing
- RGN-137
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Lenus Therapeutics, LLC
Keratoconus
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01344187
- Testing
- riboflavin solution, KXL System
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Glaukos Corporation
Degenerative Disc Disease
A Pivotal Study of rhBMP-2/ACS/INTER FIX™ Device for Posterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
The purpose of this clinical trial is to assess the safety and effectiveness of the rhBMP-2/ACS/INTER FIX™ device as compared to the autograft/INTER FIX™ device in patients with symptomatic degenerative disease.
- Trial name
- NCT01491464
- Testing
- rhBMP-2/ACS/INTER FIX™, Autogenous bone/INTER FIX™
- Volunteers
- 67 people
- Sponsor
- Medtronic Spinal and Biologics
Vascular Ehlers-Danlos Syndrome
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
The purpose of this study is to investigate the efficacy of enzastaurin compared to placebo in preventing arterial events (rupture, dissection, pseudoaneurysm, carotid-cavernous sinus fistula, or aneurysm, fatal or not) leading…
- Trial name
- PREVEnt (NCT05463679)
- Testing
- Enzastaurin
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Aytu BioPharma, Inc.
Alport Syndrome
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
The purpose of the study is to learn about the safety and tolerability of setanaxib in subjects with Alport syndrome, when added to their standard of care treatment.
- Trial name
- NCT06274489
- Testing
- Setanaxib
- Where
- 17 sites in Austria, Czechia and 3 more
- Volunteers
- 20 people
- Sponsor
- Calliditas Therapeutics AB